In this study, researchers recruited 286 patients with MRSA VAP and patients were randomized to treatment with either vancomycin or linezolid. Patients in both groups were similar with respect to demographics, severity of illness and accompanying illnesses.
At the end of treatment, the researchers found patients treated with linezolid had a clinical success rate of 78.6 percent, compared to a 65.9 percent clinical success rate in patients treated with vancomycin. At the end of the study, patients treated with linezolid had a clinical success rate of 52.1 percent, while those treated with vancomycin had a clinical success rate of 43.4 percent. Adverse events and mortality rates were similar between both groups.
Read the news release about linezolid as a treatment for MRSA.
Related Articles on MRSA:
Study: Healthcare Workers May Blame External Factors for MRSA Infections
FDA Warns Companies to Stop Making MRSA Claims for OTC Products
Wound Dressing With Silver Kills MRSA, Other Antibiotic-Resistance ‘Superbugs’
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
